Hydrafacial Introduces HydraScalp® with Keravive™ as Next Evolution in Scalp Health

An advanced, non-invasive scalp treatment with no downtime, featuring newly engineered tips and clinically proven to visibly ...
Nasdaq

Arcutis Biotherapeutics Receives FDA Approval for Once-Daily ZORYVE Foam for Scalp and Body Plaque Psoriasis Treatment

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.
Nasdaq

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

WESTLAKE VILLAGE, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno ...